Vitiligo and Insulin Resistance As a Component of Metabolic Syndrome: an Analysis

Overview

Journal Postepy Dermatol Alergol

Publisher Termedia

Specialty Allergy & Immunology

Date 2023 Sep 11

PMID 37692261

Authors

Anna Tekielak

Kornelia Pietrauszka

Bartosz Miziolek

Beata Bergler-Czop

Affiliations

Soon will be listed here.

Abstract

There have been many studies on the association between vitiligo and metabolic syndrome, while only few scientific papers on vitiligo and insulin resistance. In recent years, there have been significant developments in research to trace and understand the aetiology of both conditions. In this article we have analysed pathophysiological mechanisms and the association of insulin resistance (as a component of metabolic syndrome) and vitiligo.

Citing Articles

Risk factors for cardiovascular diseases in patients with vitiligo: an analysis of current evidence.

Liang X, Guo F, Zhang M, Wang C, Lin N, Liu L Ann Med. 2024; 56(1):2326297.

PMID: 39300810 PMC: 11418058. DOI: 10.1080/07853890.2024.2326297.

References

Shen C, Gao J, Sheng Y, Dou J, Zhou F, Zheng X . Genetic Susceptibility to Vitiligo: GWAS Approaches for Identifying Vitiligo Susceptibility Genes and Loci. Front Genet. 2016; 7:3. PMC: 4740779. DOI: 10.3389/fgene.2016.00003. View

Tang Q, Li X, Song P, Xu L . Optimal cut-off values for the homeostasis model assessment of insulin resistance (HOMA-IR) and pre-diabetes screening: Developments in research and prospects for the future. Drug Discov Ther. 2016; 9(6):380-5. DOI: 10.5582/ddt.2015.01207. View

Moretti S, Spallanzani A, Amato L, Hautmann G, Gallerani I, Fabiani M . New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions. Pigment Cell Res. 2002; 15(2):87-92. DOI: 10.1034/j.1600-0749.2002.1o049.x. View

Bhatti J, Bhatti G, Reddy P . Mitochondrial dysfunction and oxidative stress in metabolic disorders - A step towards mitochondria based therapeutic strategies. Biochim Biophys Acta Mol Basis Dis. 2016; 1863(5):1066-1077. PMC: 5423868. DOI: 10.1016/j.bbadis.2016.11.010. View

Verma D, Hussain K, Namiq K, Firoz A, Bouchama M, Raza M . Vitiligo: The Association With Metabolic Syndrome and the Role of Simvastatin as an Immunomodulator. Cureus. 2021; 13(3):e14029. PMC: 8059484. DOI: 10.7759/cureus.14029. View

Auburger G, Gispert S, Lahut S, Omur O, Damrath E, Heck M . 12q24 locus association with type 1 diabetes: SH2B3 or ATXN2?. World J Diabetes. 2014; 5(3):316-27. PMC: 4058736. DOI: 10.4239/wjd.v5.i3.316. View

Spritz R . The genetics of vitiligo. J Invest Dermatol. 2011; 131(E1):E18-20. PMC: 3513341. DOI: 10.1038/skinbio.2011.7. View

Katz A, Nambi S, Mather K, Baron A, Follmann D, Sullivan G . Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000; 85(7):2402-10. DOI: 10.1210/jcem.85.7.6661. View

Gonzalez-Saldivar G, Rodriguez-Gutierrez R, Ocampo-Candiani J, Gonzalez-Gonzalez J, Gomez-Flores M . Skin Manifestations of Insulin Resistance: From a Biochemical Stance to a Clinical Diagnosis and Management. Dermatol Ther (Heidelb). 2016; 7(1):37-51. PMC: 5336429. DOI: 10.1007/s13555-016-0160-3. View

10.

Speeckaert R, Lambert J, Bulat V, Belpaire A, Speeckaert M, van Geel N . Autoimmunity in Segmental Vitiligo. Front Immunol. 2020; 11:568447. PMC: 7655129. DOI: 10.3389/fimmu.2020.568447. View

11.

Birol A, Kisa U, Kurtipek G, Kara F, Kocak M, Erkek E . Increased tumor necrosis factor alpha (TNF-alpha) and interleukin 1 alpha (IL1-alpha) levels in the lesional skin of patients with nonsegmental vitiligo. Int J Dermatol. 2006; 45(8):992-3. DOI: 10.1111/j.1365-4632.2006.02744.x. View

12.

Napolitano M, Megna M, Monfrecola G . Insulin resistance and skin diseases. ScientificWorldJournal. 2015; 2015:479354. PMC: 4419263. DOI: 10.1155/2015/479354. View

13.

Alikhan A, Felsten L, Daly M, Petronic-Rosic V . Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011; 65(3):473-491. DOI: 10.1016/j.jaad.2010.11.061. View

14.

Lotti T, DErme A . Vitiligo as a systemic disease. Clin Dermatol. 2014; 32(3):430-4. DOI: 10.1016/j.clindermatol.2013.11.011. View

15.

Roberts G, Santorico S, Spritz R . The genetic architecture of vitiligo. Pigment Cell Melanoma Res. 2019; 33(1):8-15. PMC: 6928395. DOI: 10.1111/pcmr.12848. View

16.

Karadag A, Tutal E, Ertugrul D . Insulin resistance is increased in patients with vitiligo. Acta Derm Venereol. 2011; 91(5):541-4. DOI: 10.2340/00015555-1141. View

17.

Kang P, Zhang W, Ji Z, Shao Z, Li C . Association between vitiligo and relevant components of metabolic syndrome: a systematic review and meta-analysis. J Dtsch Dermatol Ges. 2022; 20(5):629-641. DOI: 10.1111/ddg.14717. View

18.

Matulewicz N, Karczewska-Kupczewska M . Insulin resistance and chronic inflammation. Postepy Hig Med Dosw (Online). 2016; 70(0):1245-1258. View

19.

Azzazi Y, Mostafa W, Sayed K, Alhelf M, Safwat M, Mahrous A . Support for increased cardiovascular risk in non-segmental vitiligo among Egyptians: A hospital-based, case-control study. Pigment Cell Melanoma Res. 2020; 34(3):598-604. DOI: 10.1111/pcmr.12941. View

20.

Namazi M, Rouhani S, Moarref A, Kiani M, Tabei S, Hadibarhaghtalab M . Vitiligo and Rise in Blood Pressure - a Case-Control Study in a Referral Dermatology Clinic in Southern Iran. Clin Cosmet Investig Dermatol. 2020; 13:425-430. PMC: 7319509. DOI: 10.2147/CCID.S257022. View